IMGN vs CLVS
Interesting to note that while we still do not have an approved product generating revenue we are valued more than Clovis that was a third entrant into the PARP inhibitor class which is forecasted to ring in $167M this year, posted $33M for Q2. Their market cap is $303M and $IMGN is $424M. So the promise of a first in class is better than a slow growing asset in a very competitive class of drugs. Really looking forward to what we learn at ESMO and if 632 data will be enough for special FDA consideration - fast track, breakthrough etc and to encourage Jazz to pull the trigger.